Home  |  Contact
Due to scheduled maintenance work, this service will not be available from Tuesday August 23rd 06:00 pm until Wednesday August 24th 08:00 am CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot P61586: Variant p.Glu47Lys

Transforming protein RhoA
Gene: RHOA
Variant information

Variant position:  47
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glutamate (E) to Lysine (K) at position 47 (E47K, p.Glu47Lys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (E) to large size and basic (K)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In EDFAOB; somatic mosaic variant; decreased Rho protein signal transduction; decreased substrate adhesion-dependent cell spreading; decreased number of stress fibers assembly; decreased cytoplasmic microtubule organization.
Any additional useful information about the variant.



Sequence information

Variant position:  47
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  193
The length of the canonical sequence.

Location on the sequence:   KDQFPEVYVPTVFENYVADI  E VDGKQVELALWDTAGQEDYD
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 190 Transforming protein RhoA
Modified residue 34 – 34 (Microbial infection) O-AMP-tyrosine; by Haemophilus IbpA; alternate
Modified residue 37 – 37 (Microbial infection) O-AMP-threonine; by Vibrio VopS
Modified residue 41 – 41 (Microbial infection) ADP-ribosylasparagine; by botulinum toxin
Modified residue 63 – 63 5-glutamyl serotonin
Glycosylation 34 – 34 (Microbial infection) O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230; alternate
Glycosylation 37 – 37 (Microbial infection) O-alpha-linked (GlcNAc) threonine; by C.novyi toxin TcdA; alternate
Glycosylation 37 – 37 (Microbial infection) O-linked (Glc) threonine; by C.difficile toxins TcdA and TcdB; alternate
Mutagenesis 34 – 34 Y -> A. Abolishes interaction with DGKQ.
Mutagenesis 34 – 34 Y -> F. Abolishes AMPylation by Haemophilus IbpA.
Mutagenesis 37 – 37 T -> A. Abolished monoglucosylation by C.difficile toxin TcdA. Abolished O-GlcNAcylation by C.novyi toxin TcdA.
Mutagenesis 63 – 63 Q -> L. Causes constitutive activation.
Beta strand 42 – 48


Literature citations

Postzygotic inactivating mutations of RHOA cause a mosaic neuroectodermal syndrome.
Vabres P.; Sorlin A.; Kholmanskikh S.S.; Demeer B.; St-Onge J.; Duffourd Y.; Kuentz P.; Courcet J.B.; Carmignac V.; Garret P.; Bessis D.; Boute O.; Bron A.; Captier G.; Carmi E.; Devauchelle B.; Genevieve D.; Gondry-Jouet C.; Guibaud L.; Lafon A.; Mathieu-Dramard M.; Thevenon J.; Dobyns W.B.; Bernard G.; Polubothu S.; Faravelli F.; Kinsler V.A.; Thauvin C.; Faivre L.; Ross M.E.; Riviere J.B.;
Nat. Genet. 51:1438-1441(2019)
Cited for: INVOLVEMENT IN EDFAOB; VARIANTS EDFAOB LYS-47 AND SER-71; CHARACTERIZATION OF VARIANTS EDFAOB LYS-47 AND SER-71; FUNCTION; MUTAGENESIS OF GLY-14 AND THR-19;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.